Full-Time
Updated on 8/23/2026
Enterprise AI software and consulting services
No salary listed
London, UK
Hybrid
Hybrid working is offered; specific on-site frequency is not stated.
See people who can refer or advise you
Faculty AI delivers AI-as-a-service by combining strategy, software and hands-on delivery to help organizations implement AI solutions. It builds custom AI systems across sectors like government, healthcare, retail and energy, anchored by Frontier, its decision intelligence software that simulates cause-and-effect relationships within a business. The company differentiates itself with end-to-end AI implementation and enterprise-scale delivery, drawing on a track record with clients such as the NHS, Red Bull, Virgin Media and Moonpig. Its goal is to help organizations become data-driven, improve operational efficiency and decision accuracy, and expand internationally while creating jobs.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$56.5M
Headquarters
London, United Kingdom
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Unlimited Paid Time Off
Health Insurance
Dental Insurance
Enhanced parental leave
Flexible Work Hours
Hybrid Work Options
Private healthcare and dental
Family-Friendly Flexibility & Flexible working
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Remote Work Options
Paid Vacation
Paid Holidays
Adoption Assistance
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Gym Membership
Commuter Benefits
Meal Benefits
Legal Services
Employee Discounts
Company Social Events
Faculty has launched the Frontier Life Sciences Developer Studio, an enhanced development environment for life sciences teams to build and deploy Computational Twins for clinical trial simulation. The tool aims to help pharmaceutical organisations compress planning cycles from weeks to minutes and run more efficient trials. The Studio includes embedded AI agents that diagnose bugs, reconcile data discrepancies and suggest fixes in real time across clinical trial management systems, patient enrolment data and site activation logs. This reduces debugging time and increases confidence before production deployment. Faculty, founded in 2014 and acquired by Accenture in 2026, develops the Decision Intelligence platform Faculty Frontier. The Studio is now available to all Frontier life sciences customers, enabling clinical trial teams to rapidly iterate simulation-driven decisions across the trial lifecycle.
Faculty has launched the Frontier Plug-in Marketplace, a curated ecosystem of modular plug-ins that extends its Decision Intelligence platform. The marketplace enables teams to discover, adopt and contribute plug-ins directly within existing Frontier deployments without refactoring. The marketplace addresses enterprise AI scaling challenges by providing reusable capabilities spanning data ingestion, MLOps pipelines, decision management and validation tooling. Teams can build and share their own plug-ins whilst retaining full control, with all contributions reviewed and versioned by Faculty. Available to all Frontier customers, the marketplace aims to help organisations standardise AI capabilities, accelerate deployment and improve decision-making at scale. Faculty, founded in 2014 and acquired by Accenture in 2026, develops AI products for frontier AI deployment and works with leading AI labs including OpenAI, Anthropic and Meta.
Accenture has agreed to acquire Faculty, a leading UK-based AI native services and products business built on highly technical applied AI skills and a unique decision intelligence product that features advanced simulation and optimization capabilities.
Takeover is largest-ever acquisition of a privately held UK AI start-up
Truist initiates Palantir with A buy rating. Accenture acquires rival Faculty. * REINHARDT KRAUSE * Updated 08:32 AM ET 01/06/2026 A Truist Securities analyst initiated coverage on Palantir Technologies (PLTR) on Tuesday with a buy rating and, like many other Wall Street analysts, cited its artificial intelligence prowess. But he also expects the data analytics software maker to "significantly increase capital returns over the long term" for Palantir stock. Truist Securities analyst Arvind Ramnani initiated Palantir stock with a buy rating and price target of 223. Meanwhile, Accenture (ACN) on Tuesday announced the purchase of Faculty, a U.K.-based artificial intelligence startup and rival of Palantir. Faculty's Chief Executive Officer Marc Warner will become Accenture's chief technology officer and the AI company's staff of about 400 people will join the information technology services giant. On the stock market today, Palantir stock rose a fraction to 175.15 in early trading. In the first two trading days of 2026, Palantir stock dipped over 3%. In 2025, Palantir stock rose 135% While Ramnani views Palantir as a leading artificial intelligence software provider, he also expects Palantir to significantly increase capital returns over the long term. "Now operating at a 40%-plus free cash flow margin profile, we see potential for Palantir to significantly increase capital returns over the long term," he said in a report. "While high levels of stock-based compensation had been an investor concern for some time, Palantir has shown it can operate profitably by generating positive GAAP EPS for the past 12 quarters and on track for a 13th straight quarter." As of Sept. 30, Palantir had $6.4 billion in cash and liquidity on its balance sheet. It does not currently offer a stock repurchase program or dividends. Artificial Intelligence push. Founded in 2003, Palantir provides data analytics tools to government customers for intelligence gathering, counterterrorism and military purposes. Palantir's tools are used in AI decision-making. Now Palantir aims to use generative AI to spur growth in the U.S. commercial market, such as health care and financial services. Generative AI relies on advanced reasoning models and provides novel outputs based on conversational user prompts. In 2025, Palantir hosted its eighth artificial intelligence conference for customers. Palantir initially rolled out its "Artificial Intelligence Platform" in early 2023. AIPCon showcases real-world AI use cases from customers. "We view Palantir as a best-in-class AI asset," Ramnani added. "We think Palantir is ideally positioned for increased AI adoption: Palantir holds a unique market position in our view, ideally positioned for increased AI adoption by both government organizations and enterprises. The company has provided a leading software platform that integrates large organizations' proprietary data with their operations and security to improve decision-making, which now positions Palantir to capture GenAI implementation with its AIP as organizations race to generate insights and efficiencies with the technology." Palantir stock technical ratings. Meanwhile, Palantir's Relative Strength Rating stands at 93 out of a best-possible 99. But PLTR stock holds an Accumulation/Distribution Rating of C-plus. That rating analyzes price and volume changes in a stock over the past 13 weeks of trading. A+ signifies heavy institutional buying; E means heavy selling. Think of a C grade as neutral. Also, Palantir stock holds a Composite Rating of 99 out of a best-possible 99, according to IBD Stock Checkup. IBD's Composite Rating combines five separate proprietary ratings into one easy-to-use rating. The best growth stocks have a Composite Rating of 90 or better. Follow Reinhardt Krause on X, formerly Twitter, @reinhardtk_tech for updates on artificial intelligence, cybersecurity and cloud computing.